$1.01
-0.04-3.81%
Last update: Oct 23, 4:44 PM
Coherus Oncology Inc (CHRS) Stock Price, Quote, News & History
CHRSNASDAQ
Coherus sells Udenyca franchise for up to $558.4 million, shifts focus to immuno-oncology R&D, and plans clinical trials in hepatocellular carcinoma and NSCLC.
You can purchase shares of Coherus Oncology (NASDAQ:CHRS) through any online brokerage.
Other companies in Coherus Oncology’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Coherus Oncology has a consensus price target of $7.13.
The stock price for Coherus Oncology (NASDAQ: CHRS) is $1.0104 last updated October 23, 2026 at 4:44 PM EDT.
There are no upcoming dividends for Coherus Oncology.
Coherus Oncology does not have any upcoming earnings scheduled.
There is no upcoming split for Coherus Oncology.
Coherus Oncology is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and...
